Author:
Huang Yongsheng,Liao Jianwei,Liang Faya,Lin Peiliang,Wu Sangqing,Ye Yuchu,Gao Ming,Chen Renhui,Zeng Haicang,Yin Xinke,Jiang Yuanling,Ouyang Nengtai,Han Ping,Huang Xiaoming
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference54 articles.
1. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N. Engl. J. Med.,2013
2. Pembrolizumab versus Ipilimumab in Advanced Melanoma;Robert;N. Engl. J. Med.,2015
3. Cancer immunotherapy using checkpoint blockade;Ribas;Science,2018
4. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, The Lancet;Seiwert;Oncology,2016
5. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck;Ferris;N. Engl. J. Med.,2016
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献